Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Thu, Apr 2nd, 2026

Biotechnology ETFs

A list of publicly traded biotechnology and biotech-related stocks and ETFs.
Thu, Apr 2nd, 2026

Biotechnology (biotech) ETFs are publicly traded companies that develop pharmaceutical drugs used in the treatment of disease. You can use Barchart's Biotech Stocks list to find investment opportunities and compare stocks involved in this hot industry.

View Profiles of these companies.

Biotechnology ETFs News

Penny Stock CYCN Surged More Than 300% Yesterday. Why, And Should You Chase the Rally Here?

Cyclerion stock soared on a merger agreement with privately held Korsana Biosciences. But there are ample reasons for disciplined investors to avoid chasing the rally in CYCN shares.

CYCN : 6.15 (-3.61%)
Apellis Pharma Skyrockets on Biogen Deal. Is It Too Late to Chase APLS Stock?

Apellis Pharma stock more than doubled as Biogen announced a $5.6 billion acquisition. But for investors looking to jump into APLS shares now, the ship has already sailed.

APLS : 40.41 (+0.05%)
BIIB : 177.34 (-3.50%)
Cathie Wood Adds 48K Shares to This Under-the-Radar Growth Play

Wood trimmed stakes in Nvidia, Meta, and Tesla; instead, she added this speculative biotech play.

NVDA : 177.39 (+0.93%)
META : 574.46 (-0.82%)
TSLA : 360.59 (-5.42%)
ARKG : 27.36 (+1.00%)
$SPX : 6,582.69 (+0.11%)
AMD : 217.50 (+3.47%)
ARCT : 8.03 (+2.29%)
MRNA : 49.20 (-1.66%)
Bullfrog AI Is Doubling on a Key Contract Win. Should You Buy the Penny Stock Here?

Bullfrog stock rallies on a major commercial agreement with a global pharma leader. But BFRG shares remain super unattractive to own in 2026.

BFRG : 1.2000 (-25.93%)
Anavex Life Sciences Stock Is Deeply Oversold. Should You Buy the Dip?

Anavex shares crash as the EMA indicates it won’t issue a positive opinion on its candidate Alzheimer’s drug. Here’s why long-term investors may still consider loading up on AVXL stock today.

AVXL : 2.99 (-3.55%)
FDA flags misleading claims for cancer drug by biotech billionaire Patrick Soon-Shiong

Federal health officials have issued a warning about controversial statements made by biotech billionaire Dr. Patrick Soon-Shiong about one of his company's cancer drugs

IBRX : 7.30 (+2.24%)
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.